Considering the recent progress in the treatment of LCA2 and color blindness using ocular gene therapy [1]–[5], the successful delivery of gene-replacement and other therapeutic agents into the eye has become a potentially important treatment option for many retinal diseases. Here, RPE65 is linked to Abnormal retinal morphology.